Marco Bisaglia

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4295997/publications.pdf

Version: 2024-02-01

33	1,744	257101 24	414034 32
papers	citations	h-index	g-index

33	33	33	2824
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Activation of the Nrf2 Pathway as a Therapeutic Strategy for ALS Treatment. Molecules, 2022, 27, 1471.	1.7	6
2	Metformin Repurposing for Parkinson Disease Therapy: Opportunities and Challenges. International Journal of Molecular Sciences, 2022, 23, 398.	1.8	30
3	The Regulation of MiTF/TFE Transcription Factors Across Model Organisms: from Brain Physiology to Implication for Neurodegeneration. Molecular Neurobiology, 2022, 59, 5000-5023.	1.9	3
4	DJ-1: A promising therapeutic candidate for ischemia-reperfusion injury. Redox Biology, 2021, 41, 101884.	3.9	18
5	Antioxidant Therapy in Parkinsonâ€™s Disease: Insights from Drosophila melanogaster. Antioxidants, 2020, 9, 52.	2.2	19
6	Copper Ions and Parkinsonâ€™s Disease: Why Is Homeostasis So Relevant?. Biomolecules, 2020, 10, 195.	1.8	107
7	Superoxide Dismutases SOD1 and SOD2 Rescue the Toxic Effect of Dopamine-Derived Products in Human SH-SY5Y Neuroblastoma Cells. Neurotoxicity Research, 2019, 36, 746-755.	1.3	4
8	Superoxide dismutating molecules rescue the toxic effects of PINK1 and parkin loss. Human Molecular Genetics, 2018, 27, 1618-1629.	1.4	28
9	Diabetes Mellitus as a Risk Factor for Parkinsonâ€™s Disease: a Molecular Point of View. Molecular Neurobiology, 2018, 55, 8754-8763.	1.9	53
10	Circadian Rhythm Abnormalities in Parkinsonâ€™s Disease from Humans to Flies and Back. International Journal of Molecular Sciences, 2018, 19, 3911.	1.8	33
11	Superoxide Radical Dismutation as New Therapeutic Strategy in Parkinsonâ€™s Disease. , 2018, 9, 716.		42
12	Dopamine Oxidation Products as Mitochondrial Endotoxins, a Potential Molecular Mechanism for Preferential Neurodegeneration in Parkinsonâ€™s Disease. ACS Chemical Neuroscience, 2018, 9, 2849-2858.	1.7	42
13	Recent findings on the physiological function of DJ-1: Beyond Parkinson's disease. Neurobiology of Disease, 2017, 108, 65-72.	2.1	74
14	DJ-1 as a deglycating enzyme: A unique function to explain a multifaceted protein?. Neural Regeneration Research, 2017, 12, 1797.	1.6	11
15	Editorial (Thematic Selection: Critical Analyses of Mechanism-Based Therapies Against Parkinson's) Tj ETQq1 1 0.784314 rgBT /Overlo	1.4	1
16	Superoxide Dismutase (SOD)-mimetic M40403 Is Protective in Cell and Fly Models of Paraquat Toxicity. Journal of Biological Chemistry, 2016, 291, 9257-9267.	1.6	56
17	Anti-Oxidants in Parkinson's Disease Therapy: A Critical Point of View. Current Neuropharmacology, 2016, 14, 260-271.	1.4	82
18	Analysis of the Catecholaminergic Phenotype in Human SH-SY5Y and BE(2)-M17 Neuroblastoma Cell Lines upon Differentiation. PLoS ONE, 2015, 10, e0136769.	1.1	55

#	Article	IF	Citations
19	DJ-1 Is a Copper Chaperone Acting on SOD1 Activation. Journal of Biological Chemistry, 2014, 289, 10887-10899.	1.6	76
20	Are dopamine derivatives implicated in the pathogenesis of Parkinson's disease?. Ageing Research Reviews, 2014, 13, 107-114.	5.0	66
21	Biophysical groundwork as a hinge to unravel the biology of Î±-synuclein aggregation and toxicity. Quarterly Reviews of Biophysics, 2014, 47, 1-48.	2.4	32
22	Dysfunction of dopamine homeostasis: clues in the hunt for novel Parkinson's disease therapies. FASEB Journal, 2013, 27, 2101-2110.	0.2	42
23	Dopamine-derived Quinones Affect the Structure of the Redox Sensor DJ-1 through Modifications at Cys-106 and Cys-53. Journal of Biological Chemistry, 2012, 287, 18738-18749.	1.6	61
24	Parkinsonâ€™s disease and immune system: is the culprit LRRKing in the periphery?. Journal of Neuroinflammation, 2012, 9, 94.	3.1	34
25	Human SOD2 Modification by Dopamine Quinones Affects Enzymatic Activity by Promoting Its Aggregation: Possible Implications for Parkinsonâ€™s Disease. PLoS ONE, 2012, 7, e38026.	1.1	59
26	Î±-Synuclein overexpression increases dopamine toxicity in BE(2)-M17 cells. BMC Neuroscience, 2010, 11, 41.	0.8	44
27	Structural Characterization of a High Affinity Mononuclear Site in the Copper(II)-Î±-Synuclein Complex. Journal of the American Chemical Society, 2010, 132, 18057-18066.	6.6	36
28	Molecular characterization of dopamine-derived quinones reactivity toward NADH and glutathione: Implications for mitochondrial dysfunction in Parkinson disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 699-706.	1.8	67
29	Dopamine quinones interact with Î±-synuclein to form unstructured adducts. Biochemical and Biophysical Research Communications, 2010, 394, 424-428.	1.0	83
30	Interaction Between Î±-Synuclein and Metal Ions, Still Looking for a Role in the Pathogenesis of Parkinsonâ€™s Disease. NeuroMolecular Medicine, 2009, 11, 239-251.	1.8	64
31	Structural insights on physiological functions and pathological effects of Â±â€synuclein. FASEB Journal, 2009, 23, 329-340.	0.2	129
32	Kinetic and Structural Analysis of the Early Oxidation Products of Dopamine. Journal of Biological Chemistry, 2007, 282, 15597-15605.	1.6	254
33	The 11-mer repeats of human Î±-synuclein in vesicle interactions and lipid composition discrimination: A cooperative role. Biopolymers, 2006, 84, 310-316.	1.2	33